PubMed Health⌕ Search

Biomedical subjects

J L Wiley

Publications and source records attributed to J L Wiley.

At least 55 records · Page 3Linked to original sources
PubMed1996

Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.

delta 8-Tetrahydrocannabinol (delta 8-THC) is a naturally occurring cannabinoid with a characteristic pharmacological profile of in vivo effects. Previous studies have shown that modification of the structure of delta 8-THC by inclusion of a nitrogen-containing functional group alters this profile and may alkylate the cannabinoid receptor, similar to the manner in which beta-funaltrexamine (beta-FNA) alkylates the micro-opioid receptor. Two novel analogs of delta 8-THC were synthesized: a nitrogen mustard analog with a dimethylheptyl side chain (NM-delta 8-THC) and a cyano analog with a dimethylpentyl side chain (CY-delta 8-THC). Both analogs showed high affinity for brain cannabinoid receptors and when administered acutely, produced characteristic delta 9-THC-like effects in mice, including locomotor suppression, hypothermia, antinociception and catalepsy. CY-delta 8-THC shared discriminative stimulus effects with CP 55,940; for NM-delta 8-THC, these effects also occurred, but were delayed. Although both compounds attenuated the effects of delta 9-THC in the mouse behavioral tests, evaluation of potential antagonist effects of these compounds was complicated by the fact that two injections of delta 9-THC produced similar results, suggesting that acute tolerance or desensitization might account for the observations. NM-delta 8-THC, but not CY-delta 8-THC, attenuated the discriminative stimulus effects of CP 55,940 in rats several days following injection. Hence, addition of a nitrogen-containing functional group to a traditional cannabinoid structure does not eliminate agonist effects and may produce delayed attenuation of cannabinoid-induced pharmacological effects.

Animals↗
PubMed1995

Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice.

NMDA receptor antagonists have been shown to be anxiolytic in animal models of anxiety, although they have not been tested extensively. These compounds bind to several specific sites within the NMDA-receptor complex, including the NMDA site itself, the phencyclidine site, and the strychnine-insensitive glycine site. The purpose of the present study was to examine potential anxiolytic effects of site-selective NMDA receptor antagonists in the elevated plus-maze. Drug-naive albino mice were placed in the center of an elevated maze shaped like a plus sign. Two opposing arms were enclosed by high walls; the crossing arms were open. Following injection with drug or vehicle, the number of entries and time spent in each type of arm were measured during 5-min tests. Analysis of results showed that the benzodiazepine, diazepam, and the competitive NMDA receptor antagonist, NPC 17742 (2R,4R,5S 2-amino-4,5-(1,2-cyclohexyl)-7-phosphono-heptanoic acid), increased number of open arm entries and open arm time. N-Nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor which may interfere with the transduction of NMDA receptor activation, also increased open arm entries and time; however, the magnitude of these increases was small. The phencyclidine-site NMDA receptor antagonist, phencyclidine, increased open arm entries, but failed to significantly increase open arm time. ACEA 1021 (5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione), a putative glycine-site antagonist, had significant effects only on open arm entries at the highest dose tested. These results suggest that NMDA receptor antagonists show promise as potential anxiolytic agents, but that differences among antagonists acting at different cellular sites may be expected.

Amino Acids↗
PubMed1995

Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats.

While many previous studies have shown that a variety of cannabinoids substitute and cross-substitute for delta 9-tetrahydrocannabinol (THC) in drug discrimination procedures, few have systematically examined potential THC-like effects of non-cannabinoid compounds. The purpose of the present study was to delineate further the pharmacological specificity of THC discrimination. Rats were trained to discriminate THC (3.0 mg/kg) from vehicle. Following determination of a dose-effect curve with THC, substitution tests with selected compounds from a variety of pharmacological classes, including l-phenylisopropyl adenosine, dizocilpine, dextromethorphan, clozapine, buspirone, MDL 72222, muscimol, midazolam and chlordiazepoxide, were performed. Whereas THC produced full dose-dependent substitution, substitution tests with non-cannabinoid drugs resulted in less than chance (50%) levels of responding on the THC-appropriate lever, with the exception of (+)-MDMA (2.5 mg/kg, 50%) and diazepam (3.0 mg/kg, 67%). These results are consistent with those of previous studies and suggest that the discriminative stimulus effects of THC exhibit pharmacological specificity.

Animals↗
PubMed1995

Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.

CP 55,940 is a potent synthetic bicyclic cannabinoid analog that has been used in a number of studies as a radioligand for the cannabinoid receptor. This compound shares behavioral and biochemical properties with naturally occurring cannabinoids such as delta 9-THC. The purpose of the present study was 3-fold: to establish the ability of CP 55,940 to serve as a discriminative stimulus, to determine whether this discriminative stimulus is identical to that of delta 9-THC, and to examine whether a newly developed cannabinoid antagonist, SR141716A, would antagonize the discriminative stimulus effects of CP 55,940. Rats were trained to discriminate 0.1 mg/kg CP 55,940 from vehicle in standard 2-lever operant conditioning chambers. CP 55,940 produced dose-dependent generalization from the training dose in dose-effect determinations conducted before and after testing with other drugs. The effects of the training dose of CP 55,940 were dose-dependently antagonized by co-administration of SR141716A. Results of substitution tests showed that delta 9-THC, WIN 55,212-2, and cannabinol substituted completely for CP 55,940 in a dose-dependent manner; however, CP 55,940 was approx 10-fold more potent than any of the other drugs in producing CP 55,940-like discriminative stimulus effects. Several drugs with CNS depressant properties (phencyclidine, haloperidol and diazepam) failed to produce reliable substitution for CP 55,940. These results demonstrate that CP 55,940 has discriminative stimulus effects and that it shares these effects with structurally dissimilar compounds that, like CP 55,940, bind to the cannabinoid receptor. Further, these effects are blocked by SR141716A, a cannabinoid receptor antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)

Analgesics↗
PubMed1995

Effect of repeated haloperidol administration on phencyclidine discrimination in rats.

1. Previous research has shown that acute doses of haloperidol block many of themotor stimulatory effects of phencyclidine (PCP) and other PCP-like drugs. In addition, when given acutely, haloperidol produces partial attenuation of PCP's discriminative stimulus effects in rats. 2. Haloperidol is often administered chronically in clinical situations; hence, it is important to investigate the effects of repeated, as well as acute, dosing with this drug. 3. The purpose of the present study was to examine the effects of repeated administration of haloperidol on PCP discrimination in rats. Rats were trained to discriminate PCP (2.0 mg/kg) from saline in a two-lever drug discrimination procedure and were tested with cumulative doses of PCP before and after repeated administration of saline and of haloperidol (0.5 mg/kg/day). 4. Discrimination training was suspended during the two 14-15-day repeated dosing regimens. Suspended training with repeated saline administration had little effect on the dose-effect curve for % PCP-lever responding. 5. Repeated administration of haloperidol produced some diminution of PCP discrimination. After haloperidol, the ED50 for % PCP-lever responding was 1.4 mg/kg, compared to the pre-haloperidol ED50 of 0.7 mg/kg. 6. These results are consistent with those of acute dosing studies with haloperidol in PCP-trained rats and suggest that repeated administration of haloperidol may disrupt PCP's discriminative stimulus effects, although most rats were still able to discriminate the higher doses of PCP.

Animals↗
PubMed1995

Nicotine-induced acute tolerance: studies involving schedule-controlled behavior.

The major goal of the present study was to examine acute tolerance to nicotine-induced disruption of operant behavior following a single, noncontingent injection. Rats were trained to lever press for food reinforcement under a fixed ratio-30 schedule. Once trained, rats were injected with either saline or nicotine (0.8 mg/kg) in their home cages. After either a 90- or 180-min delay, each rat was injected with nicotine (0.4 mg/kg) and placed in the operant chamber for a 30-min behavioral evaluation session. This experiment was replicated with slight modifications 1 week later. The results of the present study suggest that 0.8 mg/kg of nicotine produces acute tolerance to the response rate decreasing effects of 0.4 mg/kg of nicotine. Because the tolerance-producing dose of nicotine was injected while rats were not in the test environment, they did not have an opportunity to practice the target behavior while under the influence of the drug. Hence, the acute tolerance observed in this study appears to be, at least partly, pharmacological (vs. behavioral) in nature, and may be related to a desensitization of central nicotinic acetylcholinergic receptors (nAChRs).

Animals↗
PubMed1995

Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys.

delta 9-Tetrahydrocannabinol (delta 9-THC) discrimination has been used as an animal model of cannabis intoxication in humans. While numerous studies have examined the discriminative stimulus effects of cannabinoids in rats and pigeons, studies with monkeys have been rare. In the present study, rhesus monkeys, trained to discriminate delta 9-THC from vehicle in a two-lever drug discrimination procedure, were tested with a variety of psychoactive drugs, including cannabinoids as well as drugs from other classes. Results showed that delta 9-THC discrimination showed pharmacological specificity, in that none of the non-cannabinoid drugs fully substituted for delta 9-THC. In contrast, the classical cannabinoids, delta 9-THC and delta 8-THC, and the novel cannabinoids, WIN 55212-2 and 1-butyl-2-methyl-3-(1-naphthoyl)indole, produced full dose-dependent substitution for delta 9-THC in all monkeys. A heptyl indole derivative failed to substitute for delta 9-THC, but it also did not displace [3H] CP 55940 from its binding site. These findings are consistent with those of previous cannabinoid discrimination studies with rats and suggest that results of delta 9-THC discrimination studies in rhesus monkeys may be predictive of the subjective effects of cannabinoid drugs in humans.

Animals↗
PubMed1995

Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.

A newly developed cannabinoid antagonist, SR141716A [N-(piperidin-1-yl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxa mide hydrochloride], binds to brain cannabinoid receptors and has been shown to block characteristic pharmacological effects of the aminoalkylindole cannabinoid agonist, WIN 55,212-2 (R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpho- linyl)methyl]pyrol-(1,2,3-de]-1,4-benzoxazin-6-yl)(1-n aphthalenyl)methanone monomethanesulfonate). In the present study, the effects of this compound in an animal model of cannabis intoxication were investigated. Rats were trained to press one lever after being injected with 3 mg/kg of delta 9-tetrahydrocannabinol (delta 9-THC) and to press a second lever after injection with vehicle. Rhesus monkeys also were trained to discriminate between delta 9-THC and vehicle. Results of tests with various doses of SR141716A in combination with 3 mg/kg of delta 9-THC showed that SR141716A produced reversible, dose-dependent antagonism of the discriminative stimulus properties of delta 9-THC in rats, with recovery within 24 hr. SR141716A also blocked the discriminative stimulus effects of delta 9-THC in monkeys. Furthermore, in rats, 1 mg/kg of SR141716A produced a 12-fold rightward shift in the delta 9-THC dose-effect curve and a 43-fold rightward shift in the WIN 55,212-2 dose-effect curve. When SR141716A was administered alone, it did not substitute for delta 9-THC in rats. The present results suggest that SR141716A blocks the discriminative stimulus effects of delta 9-THC via a receptor-mediated mechanism. This drug is the first reliable antagonist of cannabinoid discrimination and would be predicted to block or reverse cannabis intoxication in humans.

Analgesics↗
PubMed1994

Effects of competitive and non-competitive N-methyl-D-aspartate (NMDA) antagonists in squirrel monkeys trained to discriminate D-CPPene (SDZ EAA 494) from vehicle.

Drug discrimination studies have proven useful for comparing and contrasting the behavioral effects of site-selective N-methyl-D-aspartate (NMDA) antagonists. This study examined the effects of competitive and non-competitive NMDA antagonists in squirrel monkeys trained to discriminate 1 mg/kg D-CPPene [D-3-(2-carboxypiperazine-4-yl)-1- propenyl-1-phosphonic acid; SDZ EAA 494] from vehicle in a two-lever drug discrimination procedure. Results show that D-CPPene and several other competitive NMDA antagonists (NPC 17742, CGS 19755, and CGP 37849) completely substituted for D-CPPene in a dose-dependent manner. In contrast, phencyclidine (PCP) and ketamine produced only partial substitution at doses that severely suppressed response rates. These results are consistent with results of earlier studies with rats and monkeys showing differences in the discriminative stimulus effects of competitive and PCP-like non-competitive NMDA antagonists. The data support the predictions (1) that D-CPPene and the other competitive NMDA antagonists tested would have similar subjective effects in humans and (2) that some differences would be found in the subjective effects of competitive NMDA antagonists and PCP-like non-competitive antagonists.

Animals↗
PubMed1994

Clozapine's effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response.

The reduction in magnitude of the startle reflex in response to a loud noise produced by prior presentation of a stimulus of lower intensity is known as prepulse inhibition (PPI). PPI may be disrupted by a variety of drugs, most notably by dopaminergic agonists such as apomorphine and by phencyclidine (PCP), and related noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Apomorphine-induced disruption of PPI is antagonized by both typical and atypical neuroleptics. The present study examined the effects of the atypical neuroleptic, clozapine, alone and in combination with PCP, on PPI in rats. The results of previous studies suggest that disruption of PPI by PCP and similar drugs is not sensitive to antagonism by typical neuroleptics such as haloperidol. The results of the present study show that clozapine's effect on PCP-induced disruption of PPI is also limited. The failure of clinically effective antipsychotics of diverse chemical classes to block the effects of PCP on PPI of acoustic startle suggest that the effects of PCP in this procedure may represent a model of attentional deficits observed in treatment-resistant schizophrenia.

Acoustic Stimulation↗
PubMed1994

Differential effects of clozapine and pimozide on fixed-ratio responding during repeated dosing.

Previous research has shown that the differential development of tolerance to the disruption of operant responding produced by repeated dosing with pimozide (PMZ) or clozapine (CLZ) can distinguish these two drugs. In the present study, the effects of PMZ (1 mg/kg) and CLZ (10 mg/kg) on response rate and response duration in rats lever pressing for food reward under a fixed-ratio 30 (FR-30) operant schedule were examined. PMZ suppressed response rates across all 10 days of drug dosing; CLZ produced an initial response rate decrease, with partial recovery (50%) occurring within the 10 day period. Similarly, PMZ produced an increase in response duration that persisted into the postdrug vehicle-injection period, while CLZ did not significantly change response duration. The prolonged suppression of FR responding produced by PMZ is similar to the lack of tolerance to this drug in other types of operant schedules. In contrast, CLZ's effects on response rate are schedule dependent. These results suggest that changes in response duration with repeated dosing may more reliably differentiate typical and atypical neuroleptics than do changes in response rate under FR schedules.

Animals↗
PubMed1993

Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys.

Previous reports have suggested that delta 9-11-tetrahydrocannabinol (delta 9-11-THC), an exocyclic analog of delta 9-tetrahydrocannabinol (delta 9-THC), may have weak agonist effects as well as antagonistic properties. The purpose of the present study was to examine the effects of delta 9-11-THC in substitution and antagonism tests in rats and in rhesus monkeys trained to discriminate delta 9-THC from vehicle in two-lever drug-discrimination procedures. The substitution studies showed that delta 9-11-THC generalizes from the training dose of delta 9-THC in rats and in monkeys, although it was less potent in both species. The magnitude of the potency difference was greater in monkeys than in rats. When administered immediately following injection with the training dose of delta 9-THC, delta 9-11-THC failed to block the delta 9-THC cue in rats and showed a lack of dose-responsive inhibition in monkeys. These results suggest that delta 9-11-THC is devoid of antagonistic properties in the drug discrimination paradigm.

Animals↗
PubMed1993

Effects of four antipsychotics on punished responding in rats.

In Experiment 1, the benzodiazepine chlordiazepoxide (CDP), two typical antipsychotics, haloperidol (HAL) and chlorpromazine (CPZ), and the atypical antipsychotic clozapine (CLZ) were evaluated for antipunishment effects in rats in a modified Geller-Seifter conflict procedure [MULT fixed interval (FI) 60-s, fixed ratio (FR) 1 (food + shock)]. In Experiment 2, CDP and thioridazine (THD) were similarly tested. CLZ (2.5 and 5.0 mg/kg), but not HAL, CPZ, or THD, selectively increased punished responding, although the magnitude of effect was smaller than that observed for CDP. Possible serotonergic mechanisms for CLZ's action in this model and the possible importance of serotonergic activity for the development of other atypical antipsychotic drugs are discussed.

Animals↗
PubMed1992

Antipunishment effects of acute and repeated administration of phencyclidine and NPC 12626 in rats.

The effects of phencyclidine (PCP) and NPC 12626 on punished responding were examined using a modified Geller-Seifter procedure in rats. Both drugs are known to antagonize N-methyl-D-aspartate (NMDA) receptor mediated neurotransmission, albeit at different sites on the NMDA receptor complex. Rats were trained to lever press for food reinforcement under a multiple schedule, with responding in one component reinforced under a fixed-interval 60-sec schedule, while each response in the other component resulted in both food and brief electric shock. Both PCP and NPC 12626 produced selective increases in punished responding, although the effects were not as large as those produced by chlordiazepoxide. Repeated daily administration of each of these drugs for 6 days resulted in increases in punished responding during different portions of the treatment. A 5 mg/kg dose of chlordiazepoxide produced increases over the last 2 days of administration. PCP (2 mg/kg) produced an increase only during the second session, whereas NPC 12626 (30 mg/kg) produced increases for all but the first and fifth days of the 6-day regimen. Both competitive and noncompetitive NMDA antagonists can have antipunishment effects in this model.

Amino Acids↗
PubMed1992

Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure.

The atypical neuroleptic clozapine has been shown to have cue properties in two-lever drug discrimination procedures. Although it has been demonstrated that clozapine acts at several types of receptors in vitro and in vivo, including dopamine, serotonin [5-hydroxytryptamine (5-HT)], and acetylcholine receptors, the mechanism of action for its discriminative stimulus properties has not yet been determined. The present study examined the effects of haloperidol (D2 dopamine antagonist), ritanserin (5-HT2 antagonist), 1-alpha H,3-alpha,5-alpha H-tropan-3yl-3,5-dichlorobenzoate (MDL 72222) (5-HT3 antagonist), and buspirone (5-HT1A agonist) in stimulus substitution tests with rats trained to discriminate clozapine (5.0 mg/kg, IP) from vehicle in a two-lever drug discrimination procedure under a fixed ratio 30 schedule of food reinforcement. Analysis of the results revealed that, while clozapine produced dose-dependent responding on the clozapine lever, haloperidol and the three serotonin drugs failed to produce full substitution for clozapine at any of the doses tested. These results suggest that the discriminative stimulus properties are not mediated by D2 dopamine receptor blockade, antagonism at 5-HT2 or 5-HT3 receptors, or agonistic activity at 5-HT1A receptors. The neural basis of clozapine's discriminative stimulus properties has not yet been determined.

Animals↗
PubMed1992

Effects of ethanol and toluene on fixed-ratio performance in short sleep and long sleep mice.

This study examined the effects of ethanol (EtOH) and toluene on fixed-ratio (FR) responding in mice selectively bred for sensitivity to the effects of EtOH on sleep time. Although the more sensitive long sleep (LS) mice showed greater EtOH-induced impairment in a motor performance task than did the less sensitive short sleep (SS) mice, changes in FR performance in the two lines did not differ in response to EtOH, regardless of route (oral or intraperitoneal) or time (40 vs. 60 min pre-session) of administration. These results emphasize the importance of considering task variables in determination of the behavior of different genotypes. In contrast to results with EtOH, the volatile inhalant toluene produced different effects on FR responding in the selected lines, with SS mice being more sensitive than LS mice.

Administration, Inhalation↗
PubMed1990

Differential effects of haloperidol and clozapine on the reinforcing efficacy of food reward in an alleyway reacquisition paradigm.

Using the alleyway reacquisition procedure developed by Horvitz and Ettenberg, the present study compared the effects of a typical neuroleptic haloperidol (0.15 and 0.30 mg/kg) to those of an atypical neuroleptic clozapine (5.0 and 10 mg/kg) on running times 24 hours after a single food-rewarded trial administered during an extinction regimen. Rats that received food reward plus an injection of vehicle or 0.15 mg/kg haloperidol ran faster on the subsequent test day than did nonrewarded rats. The 0.30 mg/kg dose of haloperidol blocked this reacquisition effect, yielding results consistent with the anhedonia hypothesis. Clozapine (5.0 and 10 mg/kg), however, failed to block the reacquisition of alleyway running. Thus, unlike haloperidol, clozapine did not produce anhedonic effects in this reacquisition paradigm. These results suggest that neither motor nor anhedonic properties of neuroleptics appear to be crucial to the clinical efficacy of neuroleptics.

Animals↗